Orniplabin

Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS[1][2].

Product Specifications

CAS Number

[733805-92-0]

Product Name Alternative

SMTP-7

UNSPSC

12352005

Target

Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/orniplabin.html

Purity

95.0

Solubility

10 mM in DMSO

Smiles

O=C1C2=C(C3=C(C[C@H](O)[C@@](CC/C=C(C)/CC/C=C(C)/C)(C)O3)C(O)=C2)CN1[C@H](C(O)=O)CCCN4CC5=C(C=C(O)C6=C5O[C@](CC/C=C(C)/CC/C=C(C)/C)(C)[C@@H](O)C6)C4=O

Molecular Formula

C51H68N2O10

Molecular Weight

869.09

References & Citations

[1]Shibata K, et al. A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382 (3) :245-53.|[2]Shibata K, et al. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384 (1) :103-8.